Royalty Pharma (Nasdaq: RPRX) has entered into an agreement with Biogen (Nasdaq: BIIB) to provide research and development (R&D) funding for the US biotech’s litifilimab.
The drug is a first-in-class investigational candidate in Phase III with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous (CLE).
Royalty Pharma said it will provide up to $250 million over six quarters to Biogen to support the development of litifilimab in exchange for regulatory milestones and mid-single digit royalties on annual worldwide sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze